---
format: html
---
<div class="center-normal" style="font-size:2em; margin-top:1em;"><strong>Peer-Reviewed Literature</strong></div>

</br>


### [1] [Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?](https://pubmed.ncbi.nlm.nih.gov/22531173/)
<a id="ross2012"></a>
Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012 Sep;36(9):1346-52. doi: 10.1097/PAS.0b013e3182556dcd. PMID: 22531173; PMCID: PMC3421030. 

### [2] [Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue](https://pubmed.ncbi.nlm.nih.gov/35987380/)
<a id="andolfi2022"></a>
Andolfi C, Vickers AJ, Cooperberg MR, Carroll PR, Cowan JE, Paner GP, Helfand BT, Liauw SL, Eggener SE. Blood Prostate-specific Antigen by Volume of Benign, Gleason Pattern 3 and 4 Prostate Tissue. Urology. 2022 Dec;170:154-160. doi: 10.1016/j.urology.2022.08.014. Epub 2022 Aug 17. PMID: 35987380; PMCID: PMC10515713. 

### [3] [Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer](https://pubmed.ncbi.nlm.nih.gov/38278665/)
<a id="vickers2024"></a>
Vickers AJ, Assel M, Cooperberg MR, Fine SW, Eggener S. Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer. Eur Urol. 2024 Jan 25:S0302-2838(24)00007-1. doi: 10.1016/j.eururo.2024.01.005. Epub ahead of print. PMID: 38278665. 

### [4] [Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer](https://pubmed.ncbi.nlm.nih.gov/35363038/)
<a id="perera2022"></a>
Perera M, Assel MJ, Benfante NE, Vickers AJ, Reuter VE, Carlsson S, Laudone V, Touijer KA, Eastham JA, Scardino PT, Fine SW, Ehdaie B. Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. J Urol. 2022 Aug;208(2):309-316. doi: 10.1097/JU.0000000000002685. Epub 2022 Apr 1. PMID: 35363038; PMCID: PMC9283280. 

### [5] [Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy](https://pubmed.ncbi.nlm.nih.gov/35813259/)
<a id="bommelaere2022"></a>
Bommelaere T, Villers A, Puech P, Ploussard G, Labreuche J, Drumez E, Leroy X, Olivier J. Risk Estimation of Metastatic Recurrence After Prostatectomy: A Model Using Preoperative Magnetic Resonance Imaging and Targeted Biopsy. Eur Urol Open Sci. 2022 May 19;41:24-34. doi: 10.1016/j.euros.2022.04.011. PMID: 35813259; PMCID: PMC9257652. 
